Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision cancer medicines, has announced inducement grants to seven new employees. The Compensation Committee approved nonstatutory stock options to purchase 82,950 shares of common stock under the company's 2023 Inducement Option Plan.
The stock options have an exercise price of $7.95 per share, matching the closing price on September 2, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.
Kura Oncology (Nasdaq: KURA), società biofarmaceutica in fase clinica specializzata in terapie oncologiche di precisione, ha comunicato l'assegnazione di incentivi azionari a sette nuovi dipendenti. Il Comitato per la retribuzione ha approvato opzioni non statutarie per l'acquisto di 82.950 azioni ordinarie ai sensi del piano di opzioni d'induzione 2023 dell'azienda.
Le opzioni hanno un prezzo di esercizio di 7,95 $ per azione, corrispondente al prezzo di chiusura del 2 settembre 2025. Le opzioni matureranno in quattro anni: il 25% dopo il primo anno e il restante 75% mensilmente nei successivi 36 mesi, subordinatamente alla permanenza in servizio.
Kura Oncology (Nasdaq: KURA), una compañía biofarmacéutica en etapa clínica centrada en medicinas oncológicas de precisión, ha anunciado concesiones de incentivos a siete nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones no estatutarias para comprar 82.950 acciones ordinarias bajo el Plan de Opciones por Inducción 2023 de la compañía.
Las opciones tienen un precio de ejercicio de 7,95 $ por acción, equivalente al precio de cierre del 2 de septiembre de 2025. Las opciones se consolidarán en cuatro años: un 25% al cabo del primer año y el resto mensualmente durante los 36 meses siguientes, condicionado a la continuidad en el empleo.
Kura Oncology (Nasdaq: KURA), 정밀 항암제 개발에 주력하는 임상 단계 바이오제약사인 이 회사는 7명의 신규 직원에게 유인성 보상을 부여했다고 발표했습니다. 보상위원회는 회사의 2023 인듀스먼트 옵션 플랜에 따라 보통주 82,950주를 매수할 수 있는 비법정 스톡옵션을 승인했습니다.
옵션의 행사가격은 주당 7.95달러로, 2025년 9월 2일 종가와 동일합니다. 옵션은 4년 동안 가속되며, 1년 후 25%가 베스팅되고 나머지는 이후 36개월 동안 매달 베스팅되며 계속 고용 상태여야 합니다.
Kura Oncology (Nasdaq: KURA), une société biopharmaceutique en phase clinique spécialisée dans les médicaments oncologiques de précision, a annoncé des attributions d'incitation à sept nouveaux employés. Le comité de rémunération a approuvé des options d'achat d'actions non statutaires permettant d'acquérir 82 950 actions ordinaires dans le cadre du plan d'options d'induction 2023 de la société.
Les options ont un prix d'exercice de 7,95 $ par action, correspondant au cours de clôture du 2 septembre 2025. Elles seront acquises sur quatre ans : 25 % après un an et le reste mensuellement sur les 36 mois suivants, sous réserve de la poursuite de l'emploi.
Kura Oncology (Nasdaq: KURA), ein biopharmazeutisches Unternehmen in klinischer Phase mit Schwerpunkt auf präzisen Krebsmedikamenten, hat die Gewährung von Anreizzuteilungen an sieben neue Mitarbeiter bekanntgegeben. Der Vergütungsausschuss genehmigte nicht-statutory Aktienoptionen zum Kauf von 82.950 Stammaktien im Rahmen des Inducement Option Plans 2023 des Unternehmens.
Der Ausübungspreis beträgt 7,95 $ je Aktie, entsprechend dem Schlusskurs vom 2. September 2025. Die Optionen werden über vier Jahre unverfallbar: 25 % nach einem Jahr, der Rest monatlich über die folgenden 36 Monate, vorausgesetzt die Beschäftigung besteht fort.
- None.
- None.
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on September 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 82,950 shares of common stock to seven (7) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
What inducement grants did Kura Oncology (KURA) announce in September 2025?
What is the vesting schedule for Kura Oncology's September 2025 inducement stock options?
What was the exercise price for KURA's September 2025 inducement stock options?
Under which plan were Kura Oncology's September 2025 inducement grants issued?
